M
Michael J. Cameron
Researcher at Brigham and Women's Hospital
Publications - 14
Citations - 4715
Michael J. Cameron is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: NUT midline carcinoma & Gene rearrangement. The author has an hindex of 10, co-authored 13 publications receiving 4031 citations. Previous affiliations of Michael J. Cameron include Harvard University & Capital Medical University.
Papers
More filters
Journal ArticleDOI
Selective inhibition of BET bromodomains.
Panagis Filippakopoulos,Jun Qi,Sarah Picaud,Yao Shen,William B. Smith,Oleg Fedorov,Elizabeth M. Morse,T. Keates,Tyler T. Hickman,I. Felletar,Martin Philpott,Shonagh Munro,Michael R. McKeown,Yuchuan Wang,Amanda L. Christie,Nathan West,Michael J. Cameron,Brian E. Schwartz,Tom D. Heightman,Nicholas B. La Thangue,Christopher A. French,Olaf Wiest,Andrew L. Kung,Stefan Knapp,Stefan Knapp,James E. Bradner +25 more
TL;DR: A cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains is reported, establishing proof-of-concept for targeting protein–protein interactions of epigenetic ‘readers’, and providing a versatile chemical scaffold for the development of chemical probes more broadly throughout the b romodomain family.
Journal ArticleDOI
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
Christopher A. French,Cherie L. Ramirez,J. Kolmakova,Tyler T. Hickman,Michael J. Cameron,M.E. Thyne,Jeffrey L. Kutok,Jeffrey A. Toretsky,A.K. Tadavarthy,Ursula R. Kees,Jonathan A. Fletcher,Jon C. Aster +11 more
TL;DR: Together, these data suggest that BRD–NUT fusion proteins contribute to carcinogenesis by associating with chromatin and interfering with epithelial differentiation.
Journal ArticleDOI
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.
Herbert Haack,Laura A. Johnson,Christopher J. Fry,Katherine Crosby,Roberto D. Polakiewicz,Edward B. Stelow,Seung-Mo Hong,Brian E. Schwartz,Michael J. Cameron,Mark A. Rubin,Martin C. Chang,Jon C. Aster,Christopher A. French +12 more
TL;DR: IHC staining with the C52 monoclonal antibody is a highly sensitive and specific test that reliably distinguishes NMC from other forms of carcinoma.
Journal ArticleDOI
Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Brian E. Schwartz,Matthias D. Hofer,Madeleine E. Lemieux,Daniel E. Bauer,Michael J. Cameron,Nathan West,Elin S. Agoston,Nicolas Reynoird,Saadi Khochbin,Tan A. Ince,Amanda L. Christie,Katherine A. Janeway,Sara O. Vargas,Antonio R. Perez-Atayde,Jon C. Aster,Stephen E. Sallan,Andrew L. Kung,James E. Bradner,Christopher A. French +18 more
TL;DR: Findings provide preclinical support for trials of HDACi in patients with NMC, and show that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression.
Journal ArticleDOI
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
Adlai R. Grayson,Erica M. Walsh,Erica M. Walsh,Michael J. Cameron,Michael J. Cameron,Jernej Godec,Todd Ashworth,Todd Ashworth,Jessica M Ambrose,Jessica M Ambrose,Alexandra B. Aserlind,Alexandra B. Aserlind,Hongfang Wang,Hongfang Wang,Gerard I. Evan,Michael J. Kluk,Michael J. Kluk,James E. Bradner,Jon C. Aster,Jon C. Aster,Christopher A. French,Christopher A. French +21 more
TL;DR: The findings support a model in which dysregulation of MYC by BRD-NUT fusion proteins has a central role in the pathogenesis of NMC, and suggest that MYC is a downstream target of BRD4-N UT that is required for maintenance of N MC cells in an undifferentiated, proliferative state.